Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.54 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.50 |
| ▸ | MC4R | P32245 | 2/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.48 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.48 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.47 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.47 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21892098 | 1.00 | RORC (0.54) | RORCUSP30MC4RCHRM2CHRM4 | |
| SCHEMBL3025628 | 1.00 | RORC (0.54) | RORCUSP30MC4RCHRM2CHRM4 | |
| SCHEMBL2780389 | 1.00 | RORC (0.54) | RORCUSP30MC4RCHRM2CHRM4 | |
| SCHEMBL5097178 | 1.00 | RORC (0.54) | RORCUSP30MC4RCHRM2CHRM4 | |
| SCHEMBL7887604 | 0.93 | RORC (0.55) | RORCUSP30CHRM2CHRM4CHRM5 | |
| SCHEMBL5839366 | 0.93 | RORC (0.55) | RORCUSP30CHRM2CHRM4CHRM5 | |
| SCHEMBL3449300 | 0.93 | RORC (0.55) | RORCUSP30CHRM2CHRM4CHRM5 | |
| SCHEMBL1891481 | 0.92 | RORC (0.55) | RORCUSP30MC4RCHRM2CHRM4 | |
| SCHEMBL2782549 | 0.90 | SLC18A2 (0.53) | RORCUSP30CHRM2CHRM4CHRM5 | |
| SCHEMBL6594128 | 0.90 | RORC (0.53) | RORCUSP30CHRM2CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10624882-B2 | Rho kinase inhibitors | AERIE PHARMACEUTICALS, INC. (US) | 2020-04-21 | — | — | US | disclosed |
| EP-2068878-B1 | RHO KINASE INHIBITORS | AERIE PHARMACEUTICALS INC (US) | 2019-04-10 | — | — | EP | disclosed |
| US-20180344723-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2018-12-06 | — | — | US | disclosed |
| US-20160243102-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2016-08-25 | — | — | US | disclosed |
| US-20150297581-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2015-10-22 | — | — | US | disclosed |
| US-20140357652-A1 | RHO KINASE INHIBITORS | ALCON INC. (CH) | 2014-12-04 | — | — | US | disclosed |
| US-8809326-B2 | Isoquinolinone Rho kinase inhibitors | AERIE PHARMACEUTICALS, INC. (US) | 2014-08-19 | — | — | US | disclosed |
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ALCON INC. (CH) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160243102-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, CIT | RORC 1386/4885USP30 2741/4885MC4R 3572/4885 |
| US-20150297581-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, CIT | RORC 1386/4885USP30 2741/4885MC4R 3572/4885 |
| US-10624882-B2 | Rho kinase inhibitors | ROCK1, ROCK2, CIT | RORC 1386/4885USP30 2741/4885MC4R 3572/4885 |
| US-20140357652-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, CIT | RORC 1386/4885USP30 2741/4885MC4R 3572/4885 |
| US-20180344723-A1 | RHO KINASE INHIBITORS | ROCK1, ROCK2, CIT | RORC 1386/4885USP30 2741/4885MC4R 3572/4885 |
| US-20080161297-A1 | e.g. N-(7-Chloro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-dimethylamino-2-phenyl-acetamide; hypertension, atherosclerosis, restenosis, stroke, heart failure, coronary vasospasm, cerebral vasospasm, ischemia/reperfusion injury, pulmonary hypertension, angina, myocardial infarction, | ROCK1, ROCK2, ARHGDIA | RORC 2578/4885USP30 4599/4885MC4R 4600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.